Drugs / IRX-010
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06356259 | Jun 2023 → Jan 2025 | — | ImmunoRx Pharma Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IRX-010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06356259 ↗ |
| Route | Intravenous | “Administered IV” NCT06356259 ↗ |